Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Multiplace Series
Hard-Shell Multiplace·2-18+ person
Pressure3 ATA
$150,000 - $400,000+
FDA-Approved Indication●●●●Strong Evidence
Hyperbaric Therapy for Radiation Injury
FDA-approved treatment for delayed radiation tissue damage — restoring blood supply to irradiated tissue through angiogenesis.
Key Takeaways
- Delayed radiation injury is one of 14 FDA-approved indications for HBOT — covered by insurance.
- HBOT increases vascular density in irradiated tissue by 75–85% through angiogenesis.
- The Marx protocol (1983) established HBOT as standard of care for osteoradionecrosis prevention.
- 5–15% of cancer survivors who received radiation therapy develop delayed radiation tissue damage.
- HBOT can benefit patients years or decades after the original radiation treatment.
- Standard protocol: 30–40 sessions at 2.0–2.4 ATA, 90–120 minutes each.
What is Radiation Injury?
Radiation therapy saves lives — but it also causes lasting tissue damage. Radiation destroys the microvasculature (small blood vessels) in treated areas, leading to progressive tissue hypoxia that can manifest months to years after treatment. Delayed radiation injury affects 5–15% of cancer survivors who received radiation therapy, causing conditions like osteoradionecrosis (jaw bone death after head/neck radiation), radiation cystitis (bladder damage), radiation proctitis (rectal bleeding), soft tissue necrosis, and non-healing wounds in irradiated fields. These conditions are notoriously difficult to treat with conventional medicine.
How Hyperbaric Therapy Helps Radiation Injury
Radiation damages tissue by destroying the microvasculature — tiny blood vessels that supply oxygen and nutrients. Without adequate blood supply, tissue becomes chronically hypoxic and cannot heal or maintain itself. HBOT directly addresses this root cause through angiogenesis — stimulating the growth of new blood vessels into irradiated tissue. At 2.0–2.4 ATA, HBOT has been shown to increase vascular density in irradiated tissue by 75–85% after 20–30 sessions. This restored blood supply allows tissue to heal, fight infection, and maintain viability. HBOT also enhances fibroblast function for collagen production, improves osteoblast activity for bone repair (critical for osteoradionecrosis), and supports immune function in previously compromised tissue.
Recommended Protocol
Pressure
2.0–2.4 ATA
Sessions
30–40 sessions
Duration
90–120 minutes per session
What Does the Evidence Say?
●●●●Strong Evidence
Delayed radiation injury has strong evidence supporting HBOT and is one of the 14 FDA-approved indications. The Marx protocol (1983) established HBOT as the standard of care for preventing osteoradionecrosis before dental extractions in irradiated jaw fields. A 2016 systematic review in the Journal of Dental Research confirmed HBOT's effectiveness for osteoradionecrosis prevention and treatment. The DAHANCA 10 trial and other studies have supported HBOT for radiation cystitis and proctitis. The UHMS recognizes delayed radiation injury as one of the strongest indications for HBOT, and most insurance plans cover treatment with appropriate documentation.
FDA-Approved Indication
Radiation Injury is one of the 14 conditions for which the FDA has approved hyperbaric oxygen therapy. Insurance coverage may be available with a physician prescription and treatment in an accredited facility.
Recommended Chambers for Radiation Injury
Based on the protocol requirements — minimum 2 ATA, Clinical Grade tier. Sorted by clinical credibility score.
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 34
Hard-Shell Monoplace·1-person
Pressure3 ATA
$50,000 - $90,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 36
Hard-Shell Monoplace·1-person
Pressure3 ATA
$55,000 - $95,000
Clinical GradeFDA Cleared
For Maximum Comfort
Perry Baromedical
Sigma 40
Hard-Shell Monoplace·1-person
Pressure3 ATA
$65,000 - $110,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 40-II
Hard-Shell Multiplace·2-person
Pressure3 ATA
$100,000 - $160,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma Elite
Hard-Shell Monoplace·1-person
Pressure3 ATA
$80,000 - $130,000
Frequently Asked Questions
Does insurance cover HBOT for radiation injury?
Yes. Delayed radiation injury is an FDA-approved indication. Medicare and most private insurers cover HBOT when treatment is prescribed by a physician and conducted in an accredited clinical facility. Documentation of the radiation history and failed conventional treatment is typically required.
How long after radiation therapy can HBOT help?
HBOT can help years or even decades after radiation therapy. The mechanism (angiogenesis in hypovascular tissue) works regardless of when the radiation was administered. Many patients are treated 5–20+ years after their original cancer treatment when delayed effects finally manifest.
What types of radiation injury does HBOT treat?
FDA-approved applications include: osteoradionecrosis (jaw bone death), radiation cystitis (bladder bleeding), radiation proctitis (rectal bleeding), soft tissue radionecrosis, non-healing wounds in irradiated fields, and prophylaxis before dental procedures in irradiated jaw fields. The Marx protocol for dental prophylaxis (20 HBOT sessions before extraction, 10 after) is one of the most established clinical protocols.
Related Conditions
Sources & References
- Marx et al. (1983) — Prevention of osteoradionecrosis: a randomized prospective clinical trial of HBOT vs penicillin
- Bennett et al. (2016) — HBOT for late radiation tissue injury, Cochrane Database of Systematic Reviews
- UHMS — Delayed Radiation Injury indication
- American Cancer Society — Radiation Therapy Side Effects
Last updated: March 2026. Data sourced from manufacturer specifications, FDA databases, and published clinical research.
Ready to compare chambers?
Use our filterable directory to find chambers that match your protocol requirements.